Yeh Chien-Hung, Walsh Shawn I, Craney Arryn, Tabor M Greg, Voica Ana-Florina, Adhikary Ramkrishna, Morris Sydney E, Romesberg Floyd E
Department of Chemistry, The Scripps Research Institute, La Jolla California 92037 United States.
ACS Med Chem Lett. 2018 Mar 15;9(4):376-380. doi: 10.1021/acsmedchemlett.8b00064. eCollection 2018 Apr 12.
β-Lactam antibiotics, one of the most important class of human therapeutics, act via the inhibition of penicillin-binding proteins (PBPs). The unparalleled success in their development has inspired efforts to develop them as inhibitors of other targets. Bacterial type I signal peptidase is evolutionarily related to the PBPs, but the stereochemistry of its substrates and its catalytic mechanism suggest that β-lactams with the 5 stereochemistry, as opposed to the 5 stereochemistry of the traditional β-lactams, would be required for inhibition. We report the synthesis and evaluation of a variety of 5 penem derivatives and identify several with promising activity against both a Gram-positive and a Gram-negative bacterial pathogen. To our knowledge these are the first 5-lactams to possess significant antibacterial activity and the first β-lactams imparted with antibacterial activity via optimization of the inhibition of a target other than a PBP. Along with the privileged status of their scaffold and the promise of bacterial signal peptidase I (SPase) as a target, this activity makes these compounds promising leads for development as novel therapeutics.
β-内酰胺抗生素是人类最重要的一类治疗药物,通过抑制青霉素结合蛋白(PBPs)发挥作用。其开发过程中取得的无与伦比的成功激发了人们将其开发为其他靶点抑制剂的努力。细菌I型信号肽酶在进化上与PBPs相关,但因其底物的立体化学结构及其催化机制表明,与传统β-内酰胺的5立体化学结构相反,抑制该酶需要具有5立体化学结构的β-内酰胺。我们报告了多种5-青霉烯衍生物的合成与评估,并鉴定出几种对革兰氏阳性和革兰氏阴性细菌病原体均具有有前景活性的衍生物。据我们所知,这些是首批具有显著抗菌活性的5-内酰胺,也是首批通过优化对除PBP以外的靶点的抑制作用而赋予抗菌活性的β-内酰胺。鉴于其骨架的特殊地位以及细菌信号肽酶I(SPase)作为靶点的前景,这种活性使这些化合物有望成为新型治疗药物开发的先导化合物。